210 results on '"Yuji Moriwaki"'
Search Results
2. Plasma brain-derived neurotrophic factor concentration is a predictor of chronic kidney disease in patients with cardiovascular risk factors - Hyogo Sleep Cardio-Autonomic Atherosclerosis study.
- Author
-
Masafumi Kurajoh, Manabu Kadoya, Akiko Morimoto, Akio Miyoshi, Akinori Kanzaki, Miki Kakutani-Hatayama, Kae Hamamoto, Takuhito Shoji, Yuji Moriwaki, Tetsuya Yamamoto, Masaaki Inaba, Mitsuyoshi Namba, and Hidenori Koyama
- Subjects
Medicine ,Science - Abstract
Brain-derived neurotrophic factor (BDNF) has been shown to have protective effects against cardiovascular diseases and death through neural and non-neural pathways via tropomyosin-related kinase B signaling. However, it is not known whether plasma BDNF concentration is a predictor of chronic kidney disease (CKD).This study was conducted as a prospective cohort study as part of the Hyogo Sleep Cardio-Autonomic Atherosclerosis.We measured plasma BDNF concentration in 324 patients without CKD, defined as an estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73m2, and with cardiovascular risk factors. As potential confounders, sleep condition, nocturnal hypertension, and autonomic function were quantitatively examined. The patients were followed for a median 37 months (range 2-59 months) and occurrence of CKD was noted.Plasma BDNF concentration was significantly and independently associated with CKD development, which occurred in 38 patients (11.7%). Kaplan-Meier analysis revealed that patients with reduced plasma BDNF concentration exhibited a significantly (p = 0.029) greater number of CKD events as compared to those with a higher concentration. Moreover, comparisons of key subgroups showed that the risk of CKD in association with low plasma BDNF concentration was more prominent in patients with a greater reduction of nocturnal systolic blood pressure, better movement index, higher standard deviations of the NN(RR) interval or average NN(RR) interval for each 5-minute period, and without past cardiovascular disease events, smoking habit, or albuminuria.Plasma BDNF concentration is an independent predictor for development of CKD in patients with cardiovascular risk factors.
- Published
- 2017
- Full Text
- View/download PDF
3. Associations of Sleep Quality and Awake Physical Activity with Fluctuations in Nocturnal Blood Pressure in Patients with Cardiovascular Risk Factors.
- Author
-
Manabu Kadoya, Hidenori Koyama, Masafumi Kurajoh, Mariko Naka, Akio Miyoshi, Akinori Kanzaki, Miki Kakutani, Takuhito Shoji, Yuji Moriwaki, Tetsuya Yamamoto, Masaaki Inaba, and Mitsuyoshi Namba
- Subjects
Medicine ,Science - Abstract
BACKGROUND:Sleep quality and awake physical activity are important behavioral factors involved in the occurrence of cardiovascular diseases, potentially through nocturnal blood pressure (BP) changes. However, the impacts of quantitatively measured sleep quality and awake physical activity on BP fluctuation, and their relationships with several candidate causal factors for nocturnal hypertension are not well elucidated. METHODS:This cross-sectional study included 303 patients registered in the HSCAA study. Measurements included quantitatively determined sleep quality parameters and awake physical activity obtained by actigraph, nocturnal systolic BP (SBP) fall [100 × (1- sleep SBP/awake SBP ratio)], apnea hypopnea index, urinary sodium and cortisol secretion, plasma aldosterone concentration and renin activity, insulin resistance index, parameters of heart rate variability (HRV), and plasma brain-derived neurotrophic factor (BDNF). RESULTS:Simple regression analysis showed that time awake after sleep onset (r = -0.150), a parameter of sleep quality, and awake physical activity (r = 0.164) were significantly correlated with nocturnal SBP fall. Among those, time awake after sleep onset (β = -0.179) and awake physical activity (β = 0.190) were significantly and independently associated with nocturnal SBP fall in multiple regression analysis. In a subgroup of patients without taking anti-hypertensive medications, both time awake after sleep onset (β = -0.336) and awake physical activity (β = 0.489) were more strongly and independently associated with nocturnal SBP falls. CONCLUSION:Sleep quality and awake physical activity were found to be significantly associated with nocturnal SBP fall, and that relationship was not necessarily confounded by candidate causal factors for nocturnal hypertension.
- Published
- 2016
- Full Text
- View/download PDF
4. Effects of Oligonol®, an oligomerized polyphenol formulated from lychee fruit, on serum concentration and urinary excretion of uric acid
- Author
-
Yuji Moriwaki, Chihiro Okuda, Asako Yamamoto, Tsuneyoshi Ka, Zenta Tsutsumi, Sumio Takahashi, Tetsuya Yamamoto, Kentaro Kitadate, and Koji Wakame
- Subjects
Polyphenol ,Uric acid ,Xanthine oxidase ,Oligonol® ,Lychee ,Nutrition. Foods and food supply ,TX341-641 - Abstract
Epidemiological observations and laboratory studies have suggested that polyphenols possess anti-inflammatory, anti-microbial, anti-carcinogenic, and antioxidant properties. However, studies assessing the effects of polyphenols on uric acid metabolism in vivo are scarce. Herein, we investigated whether a phenolic substance, Oligonol®, has effects on uric acid metabolism. In six healthy male volunteers, Oligonol® significantly decreased 1-h uric acid excretion and fractional uric acid clearance, which was accompanied by a decreased serum concentration of uric acid. In addition, an in vitro experiment showed that Oligonol® inhibited buttermilk xanthine oxidase activity in a dose-dependent manner. Together, these results suggest that Oligonol® lowers serum uric acid through inhibition of xanthine oxidase, and may be effective for prevention and treatment of hyperuricemia and/or gout.
- Published
- 2011
- Full Text
- View/download PDF
5. Successful Treatment with Intravenous Cyclophosphamide for Refractory Adult-Onset Still’s Disease
- Author
-
Yoshika Tsuji, Nozomi Iwanaga, Anna Adachi, Kinuyo Tsunozaki, Yasumori Izumi, Yuji Moriwaki, Kazuhiro Kurohama, Masahiro Ito, Atsushi Kawakami, and Kiyoshi Migita
- Subjects
Diseases of the musculoskeletal system ,RC925-935 - Abstract
We report a 64-year-old female case of intractable adult-onset Still’s disease (AOSD). Initial high-dose steroid therapy combined with cyclosporin A was ineffective against macrophage-activation syndrome (MAS), which was accompanied by the systemic type of AOSD. Treatment for MAS with intravenous cyclophosphamide resulted in remission of AOSD and a reduction in the high doses of steroids. Efficacy of biologics against MAS in AOSD is unclear. Cyclophosphamide, a conventional cytotoxic agent, should be considered as one of the therapeutic options for refractory types of AOSD with MAS.
- Published
- 2015
- Full Text
- View/download PDF
6. Plasma brain-derived neurotrophic factor and reverse dipping pattern of nocturnal blood pressure in patients with cardiovascular risk factors.
- Author
-
Manabu Kadoya, Hidenori Koyama, Akinori Kanzaki, Masafumi Kurajoh, Miki Hatayama, Jun Shiraishi, Hirokazu Okazaki, Takuhito Shoji, Yuji Moriwaki, Tetsuya Yamamoto, Masaaki Inaba, and Mitsuyoshi Namba
- Subjects
Medicine ,Science - Abstract
Basic studies have shown that brain-derived neurotrophic factor (BDNF) has critical roles in the survival, growth, maintenance, and death of central and peripheral neurons, while it is also involved in regulation of the autonomic nervous system. Furthermore, recent clinical studies have suggested potential role of plasma BDNF in the circulatory system.We investigated the mutual relationships among plasma BDNF, patterns of nocturnal blood pressure changes (dippers, non-dippers, extra-dippers, and reverse-dippers), and cardiac autonomic function as determined by heart rate variability (HRV).This was a cross-sectional study of patients registered in the Hyogo Sleep Cardio-Autonomic Atherosclerosis (HSCAA) Study from October 2010 to November 2012.Two-hundred fifty patients with 1 or more cardiovascular risk factor(s) (obesity, smoking, presence of cardiovascular event history, hypertension, dyslipidemia, diabetes mellitus, chronic kidney disease) were enrolled.Plasma BDNF levels (natural logarithm transformed) were significantly (p = 0.001) lower in reverse-dipper patients (7.18±0.69 pg/ml, mean ± SD, n = 36) as compared to dippers (7.86±0.86 pg/ml, n = 100). Multiple logistic regression analysis showed that BDNF (odds ratios: 0.417, 95% confidence interval: 0.228-0.762, P = 0.004) was the sole factor significantly and independently associated with the reverse-dippers as compared with dippers. Furthermore, plasma BDNF level was significantly and positively correlated with the time-domain (SDNN, SDANN5, CVRR) and frequency-domain (LF) of HRV parameters. Finally, multiple logistic regression analyses showed that the relationship between plasma BDNF and the reverse-dippers was weakened, yet remained significant or borderline significant even after adjusting for HRV parameters.Low plasma BDNF was independently associated with patients showing a reverse-dipper pattern of nocturnal blood pressure, in which an imbalance of cardiac autonomic function may be partly involved.
- Published
- 2014
- Full Text
- View/download PDF
7. Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy
- Author
-
Daisuke Sasaki, Yoshitaka Imaizumi, Hiroo Hasegawa, Akemi Osaka, Kunihiro Tsukasaki, Young Lim Choi, Hiroyuki Mano, Victor E. Marquez, Tomayoshi Hayashi, Katsunori Yanagihara, Yuji Moriwaki, Yasushi Miyazaki, Shimeru Kamihira, and Yasuaki Yamada
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Background Enhancer of zeste homolog 2 is a component of the Polycomb repressive complex 2 that mediates chromatin-based gene silencing through trimethylation of lysine 27 on histone H3. This complex plays vital roles in the regulation of development-specific gene expression.Design and Methods In this study, a comparative microarray analysis of gene expression in primary adult T-cell leukemia/lymphoma samples was performed, and the results were evaluated for their oncogenic and clinical significance.Results Significantly higher levels of Enhancr of zeste homolog 2 and RING1 and YY1 binding protein transcripts with enhanced levels of trimethylation of lysine 27 on histone H3 were found in adult T-cell leukemia/lymphoma cells compared with those in normal CD4+ T cells. Furthermore, there was an inverse correlation between the expression level of Enhancer of zeste homolog 2 and that of miR-101 or miR-128a, suggesting that the altered expression of the latter miRNAs accounts for the overexpression of the former. Patients with high Enhancer of zeste homolog 2 or RING1 and YY1 binding protein transcripts had a significantly worse prognosis than those without it, indicating a possible role of these genes in the oncogenesis and progression of this disease. Indeed, adult T-cell leukemia/lymphoma cells were sensitive to a histone methylation inhibitor, 3-deazaneplanocin A. Furthermore, 3-deazaneplanocin A and histone deacetylase inhibitor panobinostat showed a synergistic effect in killing the cellsConclusions These findings reveal that adult T-cell leukemia/lymphoma cells have deregulated Polycomb repressive complex 2 with over-expressed Enhancer of zeste homolog 2, and that there is the possibility of a new therapeutic strategy targeting histone methylation in this disease.
- Published
- 2011
- Full Text
- View/download PDF
8. Ectopic adrenocorticotropic hormone syndrome associated with olfactory neuroblastoma: acquirement of adrenocorticotropic hormone expression during disease course as shown by serial immunohistochemistry examinations
- Author
-
Seiichi Hirota, Takuhito Shoji, Masafumi Kurajoh, Tomonori Terada, Akio Miyoshi, Yuji Moriwaki, Yoshitane Tsukamoto, Manabu Kadoya, Yuji Nakamoto, and Hidenori Koyama
- Subjects
pathological study ,Blood Glucose ,Male ,Medicine (General) ,Hydrocortisone ,Endogeny ,Case Reports ,Octreotide ,Biochemistry ,Cushing syndrome ,Leukocyte Count ,0302 clinical medicine ,Medicine ,Ectopic adrenocorticotropic hormone ,olfactory neuroblastoma ,General Medicine ,Syndrome ,Middle Aged ,Immunohistochemistry ,030220 oncology & carcinogenesis ,Disease Progression ,hormones, hormone substitutes, and hormone antagonists ,medicine.medical_specialty ,endocrine system ,adrenocorticotropic hormone (ACTH) ,Esthesioneuroblastoma, Olfactory ,030209 endocrinology & metabolism ,Adrenocorticotropic hormone ,Disease course ,03 medical and health sciences ,R5-920 ,Adrenocorticotropic Hormone ,Fluorodeoxyglucose F18 ,Internal medicine ,Humans ,Olfactory Neuroblastoma ,business.industry ,Biochemistry (medical) ,Ectopic ACTH syndrome ,Cell Biology ,Metyrapone ,medicine.disease ,Eosinophils ,Endocrinology ,Positron-Emission Tomography ,Potassium ,business - Abstract
Ectopic adrenocorticotropic hormone (ACTH) syndrome (EAS) is a condition of endogenous hypercortisolism sustained by an extrapituitary ACTH-secreting tumor. Olfactory neuroblastoma (ONB) is a rare malignant neoplasm of the sinonasal tract and is derived from the olfactory epithelium. Because the paranasal sinus is not a common site of EAS, the development of ONB in patients with EAS is rare. We herein report the first known case of ONB with acquirement of ACTH production during the clinical course as proven by immunohistochemistry. A 50-year-old man diagnosed with ONB was referred to our department in July 2015 because of hypokalemia, hyperglycemia, decreased eosinophil and granulocyte counts, and elevated serum levels of ACTH and cortisol. Although two previous ONB biopsy specimens (2011 and 2014) showed no ACTH immunoreactivity, a newly obtained specimen in August 2015 clearly showed ACTH immunoreactivity. This is the first case of ectopic ACTH syndrome associated with an ONB that acquired the ability to express ACTH during its clinical course as shown by serial immunohistochemical examinations.
- Published
- 2018
9. Yogurt containing Lactobacillus gasseri PA-3 alleviates increases in serum uric acid concentration induced by purine ingestion: a randomized, double-blind, placebo-controlled study
- Author
-
Hidenori Koyama, Chizuru Saito, Hiroshi Tsuboi, Hirotaka Matsuda, Yamada Naruomi, Masafumi Kurajoh, Tetsuya Yamamoto, Yuji Moriwaki, Yukio Asami, and Hiroshi Kano
- Subjects
chemistry.chemical_classification ,Purine ,biology ,Serum uric acid ,Placebo-controlled study ,Urine ,Pharmacology ,Lactobacillus gasseri ,biology.organism_classification ,chemistry.chemical_compound ,chemistry ,Ingestion ,Nucleotide ,Nucleoside - Published
- 2018
10. Low sleep quality is associated with progression of arterial stiffness in patients with cardiovascular risk factors: HSCAA study
- Author
-
Manabu Kadoya, Akiko Morimoto, Takuhito Shoji, Miki Kakutani-Hatayama, Masaaki Inaba, Kae Kosaka-Hamamoto, Hidenori Koyama, Akio Miyoshi, Masafumi Kurajoh, and Yuji Moriwaki
- Subjects
Male ,Sleep Wake Disorders ,medicine.medical_specialty ,Time Factors ,Ambulatory blood pressure ,Pulse Wave Analysis ,030204 cardiovascular system & hematology ,Risk Assessment ,03 medical and health sciences ,Vascular Stiffness ,0302 clinical medicine ,Japan ,Risk Factors ,Internal medicine ,medicine ,Humans ,Heart rate variability ,Longitudinal Studies ,Prospective Studies ,Prospective cohort study ,Pulse wave velocity ,business.industry ,Actigraphy ,Middle Aged ,Prognosis ,medicine.disease ,Cardiovascular Diseases ,Disease Progression ,Arterial stiffness ,Cardiology ,Female ,Sleep ,Cardiology and Cardiovascular Medicine ,business ,Body mass index ,030217 neurology & neurosurgery ,Cohort study - Abstract
Improvement in sleep quality is considered to be a viable target for prevention and treatment of cardiovascular diseases. To gain insight into its underlying mechanisms, we evaluated the significance of objectively measured sleep quality in patients with regard to progression of arterial stiffness over a 3-year follow-up period.This prospective cohort study included 306 serial patients registered in the Hyogo Sleep Cardio-Autonomic Atherosclerosis (HSCAA) study. In addition to classical cardiovascular risk factors (body mass index, current smoking, past history of cardiovascular disease, dyslipidemia, diabetes mellitus), the participants were examined for ambulatory blood pressure (BP), apnea-hypopnea index (AHI), standard deviation of the NN (RR) interval (SDNN) for heart rate variability (HRV), and objective sleep quality using actigraphy findings. Brachial-ankle pulse wave velocity (baPWV) was measured at both baseline and follow-up (36.6 ± 6.8 months) as a parameter of arterial stiffness.Increases in PWV (%) were greater (p = 0.03) in the low sleep quality (LSQ) group (5.75 ± 1.15%) as compared to the normal sleep quality group (2.69 ± 0.85%). Patients with the greatest increase (≥20%) from baseline exhibited a significantly (p 0.05) larger percentage of LSQ (75% vs. 49.6%) as compared to those without PWV progression (0%), with the association still significant (odds ratio 3.62, 95% confidence interval 1.04-12.55, p = 0.04) even after adjustment for other clinical risk factors. For all subjects, univariate logistic regression analyses showed that diabetes and LSQ were significantly associated with the greatest increase of PWV. Comparisons of characteristics among specific subgroups showed more prominent associations of LSQ with the greatest increase of PWV in patients with greater age, dyslipidemia, and higher AHI.LSQ was associated with progression of arterial stiffness over a 3-year period, independent of cardiovascular risk factors such as BP, AHI, and HRV.
- Published
- 2018
11. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial
- Author
-
Kenjiro Kimura, Tatsuo Hosoya, Shunya Uchida, Masaaki Inaba, Hirofumi Makino, Shoichi Maruyama, Sadayoshi Ito, Tetsuya Yamamoto, Yasuhiko Tomino, Iwao Ohno, Yugo Shibagaki, Satoshi Iimuro, Naohiko Imai, Masanari Kuwabara, Hiroshi Hayakawa, Hiroshi Ohtsu, Yasuo Ohashi, Seiichi Matsuo, Hisashi Yamanaka, Tadao Akizawa, Tamio Teramoto, Hiroshi Kasanuki, Kenichi Yoshimura, Hiroshi Sato, Satoshi Horikoshi, Syoichi Maruyama, Masahiko Inaba, Yuji Moriwaki, Haruhito Uchida, Nagayuki Kaneshiro, Hidekazu Moriya, Yasuhiro Komatsu, Shinya Kaname, Kazunari Hanaoka, Makoto Ogura, Masato Ikeda, Kenji Kasai, Akira Sugiura, Kazushi Takahashi, Kenichiro Kojima, Kosaku Nitta, Hirofumi Tamai, Hiroshi Nagaya, Senji Okuno, Ryusuke Kakiya, Hiroya Takeoka, Kyouji Hirata, Kenichiro Asano, Yasuo Fukaya, Yasushi Iwaida, Yasuo Tsuneda, Shigeaki Nishimura, Takeyuki Hiramatsu, Yoshitaka Isaka, Takafumi Ito, Yukio Yuzawa, Kunihiro Yamagata, Tadashi Sofue, Yoshimi Jinguji, Keita Hirano, Kazuhiro Matsuyama, Teruhiko Mizumoto, Yuko Shibuya, Masahiro Sugawara, Moritoshi Kadomura, Yasuaki Teshima, Hiroshi Ohtani, Hiroki Kamata, Susumu Okawara, Masaki Fukushima, Katsumi Takemura, Eriko Kinugasa, Masami Kogure, and Yoichi Ehara
- Subjects
Adult ,Male ,medicine.medical_specialty ,030232 urology & nephrology ,Renal function ,Hyperuricemia ,030204 cardiovascular system & hematology ,Placebo ,Asymptomatic ,Risk Assessment ,Severity of Illness Index ,law.invention ,Gout Suppressants ,03 medical and health sciences ,0302 clinical medicine ,Febuxostat ,Sex Factors ,Randomized controlled trial ,Double-Blind Method ,Japan ,law ,Reference Values ,Internal medicine ,medicine ,Humans ,Renal Insufficiency, Chronic ,Aged ,business.industry ,Age Factors ,Middle Aged ,medicine.disease ,Clinical trial ,Treatment Outcome ,Nephrology ,Asymptomatic Diseases ,Disease Progression ,Female ,medicine.symptom ,business ,Kidney disease ,medicine.drug ,Follow-Up Studies ,Glomerular Filtration Rate - Abstract
Rationale & Objective Epidemiologic and clinical studies have suggested that urate-lowering therapy may slow the progression of chronic kidney disease (CKD). However, definitive evidence is lacking. Study Design Randomized, double-blind, placebo-controlled trial. Setting & Participants 467 patients with stage 3 CKD and asymptomatic hyperuricemia at 55 medical institutions in Japan. Intervention Participants were randomly assigned in a 1:1 ratio to receive febuxostat or placebo for 108 weeks. Outcomes The primary end point was the slope (in mL/min/1.73 m2 per year) of estimated glomerular filtration rate (eGFR). Secondary end points included changes in eGFRs and serum uric acid levels at 24, 48, 72, and 108 weeks of follow-up and the event of doubling of serum creatinine level or initiation of dialysis therapy. Results Of 443 patients who were randomly assigned, 219 and 222 assigned to febuxostat and placebo, respectively, were included in the analysis. There was no significant difference in mean eGFR slope between the febuxostat (0.23 ± 5.26 mL/min/1.73 m2 per year) and placebo (−0.47 ± 4.48 mL/min/1.73 m2 per year) groups (difference, 0.70; 95% CI, −0.21 to 1.62; P = 0.1). Subgroup analysis demonstrated a significant benefit from febuxostat in patients without proteinuria (P = 0.005) and for whom serum creatinine concentration was lower than the median (P = 0.009). The incidence of gouty arthritis was significantly lower (P = 0.007) in the febuxostat group (0.91%) than in the placebo group (5.86%). Adverse events specific to febuxostat were not observed. Limitations GFR was estimated rather than measured, and patients with stages 4 and 5 CKD were excluded. Conclusions Compared to placebo, febuxostat did not mitigate the decline in kidney function among patients with stage 3 CKD and asymptomatic hyperuricemia. Funding Funded by Teijin Pharma Limited. Trial Registration Registered at the UMIN (University Hospital Medical Information Network) Clinical Trials Registry with study number UMIN000008343.
- Published
- 2018
12. Nonpharmacological Management of Gout and Hyperuricemia: Hints for Better Lifestyle
- Author
-
Yuji Moriwaki, Mitsuyoshi Namba, Masafumi Kurajoh, Hirokazu Okazaki, Tetsuya Yamamoto, Zenta Tsutsumi, Takuhito Shoji, Miki Kakutani-Hatayama, Manabu Kadoya, and Hidenori Koyama
- Subjects
musculoskeletal diseases ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Analytic Reviews ,Mediterranean diet ,Medicine (miscellaneous) ,030204 cardiovascular system & hematology ,Excretion ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Weight loss ,Adenine nucleotide ,Internal medicine ,medicine ,Hyperuricemia ,030203 arthritis & rheumatology ,Vitamin C ,business.industry ,Health Policy ,Public Health, Environmental and Occupational Health ,nutritional and metabolic diseases ,medicine.disease ,Gout ,Endocrinology ,chemistry ,Physical therapy ,Uric acid ,medicine.symptom ,business - Abstract
We reviewed lifestyle factors that influence serum uric acid levels and risk of gout flare, and how to improve their deleterious effects. Since obesity increases uric acid and weight gain increases gout risk, weight reduction by daily exercise and limiting intake of excess calories is recommended. However, strenuous exercise, which causes adenine nucleotide degradation; starvation, which decreases uric acid excretion; and dehydration may raise the level of uric acid in serum and trigger gout. Increased intake of purine-rich foods, such as meat and seafood, raise the level of uric acid in serum and is associated with increased risk of gout, whereas dairy products, especially low-fat types, are associated with a lower risk of gout. Also, heavy alcohol drinking raises the uric acid level and increases the risk of gout through adenine nucleotide degradation and lactate production. Sweet fruits and soft drinks containing fructose should be moderated, since fructose may raise uric acid and increase gout risk through uric acid production and/or decreased excretion. On the other hand, the Mediterranean diet is recommended for gout patients, since it may also help prevent hyperuricemia. Furthermore, coffee and vitamin C supplementation could be considered as preventive measures, as those can lower serum uric acid levels as well as the risk of gout.
- Published
- 2015
13. Acute Effects of Oral Tofisopam on Plasma Concentration and Urinary Excretion of Uric Acid and Oxypurinol 'Preliminary Communication'
- Author
-
Miki Hatayama, Masafumi Kurajoh, Chihiro Sumida, Takashi Yamamoto, Zenta Tsutsumi, Takuhito Shoji, Jun Shiraishi, Hirokazu Okazaki, Hidenori Koyama, Yuji Moriwaki, and Mitsuyoshi Namba
- Subjects
medicine.medical_specialty ,Fenofibrate ,business.industry ,nutritional and metabolic diseases ,Allopurinol ,Tofisopam ,General Medicine ,medicine.disease ,Gout ,chemistry.chemical_compound ,Endocrinology ,Losartan ,chemistry ,Oral administration ,Internal medicine ,medicine ,Uric acid ,Pharmacology (medical) ,Hyperuricemia ,General Pharmacology, Toxicology and Pharmaceutics ,business ,medicine.drug - Abstract
The effects of tofisopam, a GABA-receptor agonist, following oral administration (300mg) with and without allopurinol pretreatment on the plasma concentration and renal transport of uric acid and oxypurinol were investigated in 5 healthy subjects. Fractional and urinary excretions of uric acid were both significantly increased at 2-3 hours after tofisopam administration (559% and 459%, respectively), while plasma uric acid concentration was significantly decreased (36%) at 2.5 hours, suggesting that tofisopam affects uric acid metabolism via the tubular transport system. The hypouricemic effect of tofisopam was comparable to or greater than that of losartan and/or fenofibrate, which also have uric acid-lowering activity. In addition, with prior administration of allopurinol, the fractional and urinary excretions of oxypurinol were increased at 2-3 hours after tofisopam administration (51% and 33%, respectively), while the plasma oxypurinol concentration was significantly decreased at 1.5 and 2.5 hours (15% and 21%, respectively). Accordingly, tofisopam may be an attractive compound for treatment of hyperuricemia and/or gout, especially in patients complicated with autonomic dysfunction symptoms, though it is possible that the uric acid-lowering effect of oxypurinol is attenuated by tofisopam.
- Published
- 2015
14. Successful Treatment with Intravenous Cyclophosphamide for Refractory Adult-Onset Still’s Disease
- Author
-
Atsushi Kawakami, Anna Adachi, Nozomi Iwanaga, Yuji Moriwaki, Masahiro Ito, Kazuhiro Kurohama, Kinuyo Tsunozaki, Yoshika Tsuji, Yasumori Izumi, and Kiyoshi Migita
- Subjects
musculoskeletal diseases ,Adult-onset Still's disease ,medicine.medical_specialty ,lcsh:Diseases of the musculoskeletal system ,Cyclophosphamide ,business.industry ,fungi ,Case Report ,General Medicine ,Pharmacology ,Gastroenterology ,body regions ,Steroid therapy ,Intravenous cyclophosphamide ,Refractory ,Cyclosporin a ,Internal medicine ,High doses ,Medicine ,lipids (amino acids, peptides, and proteins) ,lcsh:RC925-935 ,business ,hormones, hormone substitutes, and hormone antagonists ,medicine.drug - Abstract
We report a 64-year-old female case of intractable adult-onset Still’s disease (AOSD). Initial high-dose steroid therapy combined with cyclosporin A was ineffective against macrophage-activation syndrome (MAS), which was accompanied by the systemic type of AOSD. Treatment for MAS with intravenous cyclophosphamide resulted in remission of AOSD and a reduction in the high doses of steroids. Efficacy of biologics against MAS in AOSD is unclear. Cyclophosphamide, a conventional cytotoxic agent, should be considered as one of the therapeutic options for refractory types of AOSD with MAS.
- Published
- 2015
15. Anaplastic Thyroid Carcinoma Accompanied by Uncontrollable Eosinophilia
- Author
-
Miki Hatayama, Tetsuya Yamamoto, Yasu-aki Tsuchida, Mitsuyoshi Namba, Yoshitane Tsukamoto, Seiichi Hirota, Mariko Naka, Naoyoshi Onoda, Takuhito Shoji, Jun Shiraishi, Masafumi Kurajoh, Hidenori Koyama, Miwako Seki, Hirokazu Okazaki, and Yuji Moriwaki
- Subjects
Male ,medicine.medical_specialty ,Thyroid Carcinoma, Anaplastic ,Gastroenterology ,Thyroid carcinoma ,Fatal Outcome ,Internal medicine ,Eosinophilia ,Internal Medicine ,medicine ,Humans ,Thyroid Neoplasms ,Interleukin 5 ,Thyroid cancer ,Aged ,business.industry ,Granulocyte-Macrophage Colony-Stimulating Factor ,Cancer ,Interleukin ,General Medicine ,medicine.disease ,Dyspnea ,Immunology ,Etiology ,Interleukin-3 ,Interleukin-5 ,medicine.symptom ,business ,Rare disease - Abstract
Anaplastic thyroid carcinoma is a rare disease, and cases associated with eosinophilia are even rarer. We herein report a case of anaplastic thyroid carcinoma accompanied by remarkable and uncontrollable eosinophilia. A 71-year-old man was diagnosed with end-stage anaplastic thyroid carcinoma. Throughout the aggressive clinical course of the cancer, eosinophilia dramatically progressed and became extremely refractory to steroid treatment. We measured the serum levels of hematopoietic cytokines potentially involved in eosinophilia, including granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3 and IL-5. Although the GM-CSF level was moderately elevated, both the IL-3 and IL-5 levels were within the normal ranges. In this case, the patient's eosinophilia may have been related to his severe dyspnea and was likely responsible for the allergic reaction to the anticancer drug. Therefore, it is essential to elucidate the etiology of eosinophilia in patients with thyroid cancer in order to improve the treatment for patients with anaplastic thyroid carcinoma.
- Published
- 2015
16. Plasma brain-derived neurotrophic factor concentration is a predictor of chronic kidney disease in patients with cardiovascular risk factors – Hyogo Sleep Cardio-Autonomic Atherosclerosis study
- Author
-
Masaaki Inaba, Mitsuyoshi Namba, Hidenori Koyama, Akiko Morimoto, Akio Miyoshi, Tetsuya Yamamoto, Masafumi Kurajoh, Manabu Kadoya, Kae Hamamoto, Takuhito Shoji, Miki Kakutani-Hatayama, Yuji Moriwaki, and Akinori Kanzaki
- Subjects
Male ,Physiology ,lcsh:Medicine ,Blood Pressure ,Comorbidity ,030204 cardiovascular system & hematology ,Cardiovascular Medicine ,Vascular Medicine ,0302 clinical medicine ,Endocrinology ,Japan ,Risk Factors ,Blood plasma ,Chronic Kidney Disease ,Medicine and Health Sciences ,Prospective Studies ,Prospective cohort study ,lcsh:Science ,Multidisciplinary ,Smoking ,Middle Aged ,Body Fluids ,Blood ,Nephrology ,Cardiovascular Diseases ,Hypertension ,Cardiology ,Female ,medicine.symptom ,Anatomy ,Research Article ,Glomerular Filtration Rate ,Adult ,Sleep Wake Disorders ,medicine.medical_specialty ,Endocrine Disorders ,Renal function ,Blood Plasma ,03 medical and health sciences ,Internal medicine ,Diabetes mellitus ,medicine ,Diabetes Mellitus ,Humans ,Obesity ,Renal Insufficiency, Chronic ,Aged ,Dyslipidemias ,Proportional Hazards Models ,Brain-derived neurotrophic factor ,business.industry ,Brain-Derived Neurotrophic Factor ,lcsh:R ,Biology and Life Sciences ,medicine.disease ,Atherosclerosis ,Blood pressure ,Dyslipidemia ,Metabolic Disorders ,Albuminuria ,lcsh:Q ,business ,Physiological Processes ,Sleep ,030217 neurology & neurosurgery ,Biomarkers ,Kidney disease ,Follow-Up Studies - Abstract
Background Brain-derived neurotrophic factor (BDNF) has been shown to have protective effects against cardiovascular diseases and death through neural and non-neural pathways via tropomyosin-related kinase B signaling. However, it is not known whether plasma BDNF concentration is a predictor of chronic kidney disease (CKD). Design This study was conducted as a prospective cohort study as part of the Hyogo Sleep Cardio-Autonomic Atherosclerosis. Methods We measured plasma BDNF concentration in 324 patients without CKD, defined as an estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73m2, and with cardiovascular risk factors. As potential confounders, sleep condition, nocturnal hypertension, and autonomic function were quantitatively examined. The patients were followed for a median 37 months (range 2–59 months) and occurrence of CKD was noted. Results Plasma BDNF concentration was significantly and independently associated with CKD development, which occurred in 38 patients (11.7%). Kaplan-Meier analysis revealed that patients with reduced plasma BDNF concentration exhibited a significantly (p = 0.029) greater number of CKD events as compared to those with a higher concentration. Moreover, comparisons of key subgroups showed that the risk of CKD in association with low plasma BDNF concentration was more prominent in patients with a greater reduction of nocturnal systolic blood pressure, better movement index, higher standard deviations of the NN(RR) interval or average NN(RR) interval for each 5-minute period, and without past cardiovascular disease events, smoking habit, or albuminuria. Conclusions Plasma BDNF concentration is an independent predictor for development of CKD in patients with cardiovascular risk factors.
- Published
- 2017
17. Serum Macro TSH Level is Associated with Sleep Quality in Patients with Cardiovascular Risks – HSCAA Study
- Author
-
Akiko Morimoto, Miki Kakutani, Sachie Koyama, Mitsuyoshi Namba, Masaaki Inaba, Takuhito Shoji, Manabu Kadoya, Kae Hamamoto, Akio Miyoshi, Tetsuya Yamamoto, Hidenori Koyama, Yuji Moriwaki, Masahiro Koshiba, and Masafumi Kurajoh
- Subjects
Male ,Glycosylation ,endocrine system diseases ,Thyrotropin ,Stimulation ,Polysomnography ,030204 cardiovascular system & hematology ,0302 clinical medicine ,Risk Factors ,Protein Isoforms ,Multidisciplinary ,medicine.diagnostic_test ,Smoking ,Middle Aged ,Sleep in non-human animals ,Circadian Rhythm ,Hypertension ,Chromatography, Gel ,Female ,hormones, hormone substitutes, and hormone antagonists ,Adult ,endocrine system ,medicine.medical_specialty ,030209 endocrinology & metabolism ,Article ,03 medical and health sciences ,Diabetes mellitus ,Internal medicine ,Diabetes Mellitus ,medicine ,Humans ,Obesity ,Circadian rhythm ,Renal Insufficiency, Chronic ,Aged ,Dyslipidemias ,business.industry ,Actigraphy ,Atherosclerosis ,medicine.disease ,stomatognathic diseases ,Cross-Sectional Studies ,Endocrinology ,Sleep ,business ,Protein Processing, Post-Translational ,Hormone - Abstract
Macro thyroid-stimulating hormone (TSH) has been reported to be associated with seasonality and regulated by changes in day length in rodents, different from free TSH. In the present study, we investigated structural differences between macro TSH and free TSH levels in human serum, as well as the association of macro TSH with sleep quality. We enrolled 314 patients registered in the Hyogo Sleep Cardio-Autonomic Atherosclerosis (HSCAA) study. Sleep quality shown by actigraphy, sleep physical activity, and percent sleep in all and TSH closely matched subjects were significantly associated with high macro TSH levels. Macro and free TSH were similarly increased following thyrotropin-releasing hormone (TRH) stimulation, while circadian changes associated with those were distinct. To further analyze the structure of macro TSH, serum samples were separated by gel filtration chromatography. Although treatment with glycosidase did not affect morbidity, the macro TSH fraction had a markedly low affinity to the Con A column as compared with free TSH, indicating a distinct glycosylation structure. In conclusion, an increase in serum macro TSH is associated with low sleep quality and regulated in a manner distinct from free TSH, potentially due to an altered glycosylation structure.
- Published
- 2017
- Full Text
- View/download PDF
18. Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: Study by the Nagasaki CML Study Group
- Author
-
Daisuke Imanishi, Shimeru Kamihira, Reishi Yamasaki, Makiko Horai, Katsunori Yanagihara, Hisashi Soda, Daisuke Sasaki, Kensuke Horio, Tatsuro Joh, Yasuhisa Kawaguchi, Daisuke Ogawa, Masatoshi Matsuo, Emi Matsuo, Koji Ando, Takuya Fukushima, Jun Nakashima, Jun Taguchi, Tomoko Hata, Yasushi Miyazaki, Hideki Tsushima, Junnya Makiyama, Shinichiro Yoshida, Yoshitaka Imaizumi, Yuji Moriwaki, Hiroaki Taniguchi, Hiroaki Nonaka, Yumi Takasaki, Masao Tomonaga, Hidehiro Itonaga, Yukiyoshi Moriuchi, Hiroo Hasegawa, Sayaka Mori, Yuko Doi, Masataka Taguchi, Yasushi Sawayama, Kazuhiro Nagai, Takeharu Kato, and Shinya Sato
- Subjects
Male ,Cancer Research ,DNA Mutational Analysis ,Resistance ,Fusion Proteins, bcr-abl ,medicine.disease_cause ,Piperazines ,Tyrosine-kinase inhibitor ,Fusion gene ,Japan ,Risk Factors ,hemic and lymphatic diseases ,Prospective Studies ,Aged, 80 and over ,Mutation ,Gene Expression Regulation, Leukemic ,Reverse Transcriptase Polymerase Chain Reaction ,Hematology ,Middle Aged ,Treatment Outcome ,Oncology ,Benzamides ,Leukemia, Myeloid, Chronic-Phase ,Imatinib Mesylate ,Female ,Tyrosine kinase ,Chronic myelogenous leukemia ,medicine.drug ,Adult ,Adolescent ,medicine.drug_class ,Chronic phase chronic myelogenous leukemia ,Young Adult ,medicine ,Humans ,Protein Kinase Inhibitors ,Aged ,Analysis of Variance ,Dose-Response Relationship, Drug ,business.industry ,Imatinib ,medicine.disease ,BCR-ABL1 ,respiratory tract diseases ,Pyrimidines ,Protein kinase domain ,Drug Resistance, Neoplasm ,Immunology ,Cancer research ,business ,Alternative splicing - Abstract
An appropriate trigger for BCR-ABL1 mutation analysis has not yet been established in unselected cohorts of chronic-phase chronic myelogenous leukemia patients. We examined 92 patients after 12 months of tyrosine kinase inhibitor (TKI) treatment in Nagasaki Prefecture, Japan. Univariate analysis revealed that significant factors associated with not attaining a major molecular response (MMR) were the presence of the minor BCR-ABL1 fusion gene, a low daily dose of TKI, and the emergence of BCR-ABL1 kinase domain mutations conferring resistance to imatinib. Factors associated with the loss of sustained MMR were a low daily dose of TKI and the emergence of alternatively spliced BCR-ABL1 mRNA with a 35-nucleotide insertion. Taken together, our results suggest that the search for BCR-ABL1 mutations should be initiated if patients have not achieved MMR following 12 months of TKI treatment., Leukemia Research, 38(1), pp.76-83; 2014
- Published
- 2014
19. Concomitant Cushing's Disease and Marked Hyperprolactinemia: Response to a Dopamine Receptor Agonist
- Author
-
Mitsuyoshi Namba, Hirokazu Okazaki, Tetsuya Yamamoto, Takuhito Shoji, Jun Shiraishi, Manabu Shirakawa, Hidenori Koyama, Yuji Moriwaki, Reiichi Ishikura, and Masafumi Kurajoh
- Subjects
Agonist ,Adult ,endocrine system ,medicine.medical_specialty ,Cabergoline ,Hydrocortisone ,medicine.drug_class ,medicine.medical_treatment ,030209 endocrinology & metabolism ,Cushingoid ,03 medical and health sciences ,0302 clinical medicine ,Adrenocorticotropic Hormone ,Internal medicine ,Internal Medicine ,medicine ,Humans ,Pituitary Neoplasms ,Prolactinoma ,Ergolines ,Pituitary ACTH Hypersecretion ,Transsphenoidal surgery ,business.industry ,General Medicine ,Cushing's disease ,medicine.disease ,Prolactin ,Hyperprolactinemia ,Endocrinology ,Dopamine Agonists ,Amenorrhea ,Female ,medicine.symptom ,business ,hormones, hormone substitutes, and hormone antagonists ,030217 neurology & neurosurgery ,medicine.drug - Abstract
A 38-year-old woman was admitted to our hospital because of amenorrhea, multiple bone fractures, and a Cushingoid appearance. Endocrinological investigations revealed that she had co-existing Cushing's disease and prolactinoma, with a serum level of prolactin (PRL) at 1,480 ng/mL, corticotropin (ACTH) at 81.3 pg/mL, and cortisol at 16.6 μg/dL. Due to the lack of indication for transsphenoidal surgery, cabergoline monotherapy was initiated. A 6-month course of treatment resulted in only subtle amelioration of hypercortisolism, while hyperprolactinemia was dramatically improved. In 5 cases of bihormonal (ACTH/PRL) pituitary macroadenoma reported in the English literature, 2 were initially treated with dopaminergic agonists with substantial effectiveness for both PRL and ACTH. We herein report an extremely rare case of bihormonal macroadenoma in which only PRL was responsive to treatment.
- Published
- 2016
20. Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy
- Author
-
Yasuaki Yamada, Tomayoshi Hayashi, Katsunori Yanagihara, Akemi Osaka, Shimeru Kamihira, Kunihiro Tsukasaki, Hiroo Hasegawa, Young Lim Choi, Yoshitaka Imaizumi, Yasushi Miyazaki, Daisuke Sasaki, Hiroyuki Mano, Victor E. Marquez, and Yuji Moriwaki
- Subjects
CD4-Positive T-Lymphocytes ,Epigenomics ,Adenosine ,Indoles ,medicine.drug_class ,Blotting, Western ,Biology ,Hydroxamic Acids ,Methylation ,Histones ,chemistry.chemical_compound ,Histone H3 ,Cell Line, Tumor ,Panobinostat ,Histone methylation ,medicine ,Humans ,Leukemia-Lymphoma, Adult T-Cell ,Enhancer of Zeste Homolog 2 Protein ,Cell Proliferation ,Oligonucleotide Array Sequence Analysis ,Polycomb Repressive Complex 1 ,Regulation of gene expression ,Base Sequence ,Gene Expression Regulation, Leukemic ,Reverse Transcriptase Polymerase Chain Reaction ,Gene Expression Profiling ,Lysine ,EZH2 ,Histone deacetylase inhibitor ,Intracellular Signaling Peptides and Proteins ,Polycomb Repressive Complex 2 ,Original Articles ,Hematology ,Molecular biology ,DNA-Binding Proteins ,Repressor Proteins ,MicroRNAs ,chemistry ,Histone methyltransferase ,Cancer research ,Transcription Factors - Abstract
Background Enhancer of zeste homolog 2 is a component of the Polycomb repressive complex 2 that mediates chromatin-based gene silencing through trimethylation of lysine 27 on histone H3. This complex plays vital roles in the regulation of development-specific gene expression. Design and Methods In this study, a comparative microarray analysis of gene expression in primary adult T-cell leukemia/lymphoma samples was performed, and the results were evaluated for their oncogenic and clinical significance. Results Significantly higher levels of Enhancr of zeste homolog 2 and RING1 and YY1 binding protein transcripts with enhanced levels of trimethylation of lysine 27 on histone H3 were found in adult T-cell leukemia/lymphoma cells compared with those in normal CD4+ T cells. Furthermore, there was an inverse correlation between the expression level of Enhancer of zeste homolog 2 and that of miR-101 or miR-128a, suggesting that the altered expression of the latter miRNAs accounts for the overexpression of the former. Patients with high Enhancer of zeste homolog 2 or RING1 and YY1 binding protein transcripts had a significantly worse prognosis than those without it, indicating a possible role of these genes in the oncogenesis and progression of this disease. Indeed, adult T-cell leukemia/lymphoma cells were sensitive to a histone methylation inhibitor, 3-deazaneplanocin A. Furthermore, 3-deazaneplanocin A and histone deacetylase inhibitor panobinostat showed a synergistic effect in killing the cells Conclusions These findings reveal that adult T-cell leukemia/lymphoma cells have deregulated Polycomb repressive complex 2 with over-expressed Enhancer of zeste homolog 2, and that there is the possibility of a new therapeutic strategy targeting histone methylation in this disease.
- Published
- 2011
21. Effects of Oligonol®, an oligomerized polyphenol formulated from lychee fruit, on serum concentration and urinary excretion of uric acid
- Author
-
Tetsuya Yamamoto, Chihiro Okuda, Koji Wakame, Asako Yamamoto, Sumio Takahashi, Yuji Moriwaki, Zenta Tsutsumi, Kentaro Kitadate, and Tsuneyoshi Ka
- Subjects
Polyphenol ,Antioxidant ,medicine.medical_treatment ,Medicine (miscellaneous) ,Pharmacology ,urologic and male genital diseases ,chemistry.chemical_compound ,medicine ,TX341-641 ,Xanthine oxidase ,Hyperuricemia ,Oligonol ,Oligonol® ,Nutrition and Dietetics ,Lychee ,Nutrition. Foods and food supply ,Chemistry ,nutritional and metabolic diseases ,Metabolism ,medicine.disease ,Gout ,Biochemistry ,Uric acid ,Food Science - Abstract
Epidemiological observations and laboratory studies have suggested that polyphenols possess anti-inflammatory, anti-microbial, anti-carcinogenic, and antioxidant properties. However, studies assessing the effects of polyphenols on uric acid metabolism in vivo are scarce. Herein, we investigated whether a phenolic substance, Oligonol®, has effects on uric acid metabolism. In six healthy male volunteers, Oligonol® significantly decreased 1-h uric acid excretion and fractional uric acid clearance, which was accompanied by a decreased serum concentration of uric acid. In addition, an in vitro experiment showed that Oligonol® inhibited buttermilk xanthine oxidase activity in a dose-dependent manner. Together, these results suggest that Oligonol® lowers serum uric acid through inhibition of xanthine oxidase, and may be effective for prevention and treatment of hyperuricemia and/or gout.
- Published
- 2011
22. RETRACTED: Effects of ethanol on monosodium urate crystal-induced inflammation
- Author
-
Sumio Takahashi, Tetsuya Yamamoto, Asako Yamamoto, Tuneyoshi Ka, Yuji Moriwaki, Daisuke Tamada, Taku Inokuchi, and Zenta Tsutsumi
- Subjects
0301 basic medicine ,Neutrophils ,medicine.medical_treatment ,p38 mitogen-activated protein kinases ,Immunology ,Inflammation ,Biochemistry ,Monocytes ,Proinflammatory cytokine ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,In vivo ,Cell Line, Tumor ,Leukocytes ,medicine ,Animals ,Humans ,Immunology and Allergy ,Molecular Biology ,Ethanol ,Chemistry ,Monocyte ,Hematology ,Molecular biology ,Uric Acid ,Mice, Inbred C57BL ,Cytosol ,IκBα ,Cytokine ,030104 developmental biology ,medicine.anatomical_structure ,Female ,Inflammation Mediators ,medicine.symptom ,Crystallization - Abstract
To investigate whether ethanol is able to decrease monosodium urate (MSU) crystal-induced inflammation, differentiated THP1 cells from a human monocyte cell line were cultured in the presence or absence of MSU crystals with and without ethanol. In an in vivo experiment, MSU crystals were administered into subcutaneous air pouches created in mice, following peritoneal injection of ethanol diluted with PBS. MSU crystals (0.75 mg/ml) stimulated the secretion of TNF-α, IL-8, and IL-1β from THP1 cells, while ethanol at a concentration of 0.8% reduced those increases by 1.79-, 1.63-, and 1.75-fold, respectively. In vitro , MSU crystals (0.75 mg/ml) significantly increased the expression of phosphorylated JNK, ERK1/2, and p38 proteins in THP1 cells, while ethanol at a concentration of 0.8% reduced those increased expressions by 1.28-, 1.14-, and 1.68-fold, respectively. In addition, MSU crystals (0.75 mg/ml) significantly increased the expression of phosphorylated NF-κB protein in the nuclear and cytosolic fractions and decreased the expression of IκBα in the cytosolic fraction. Ethanol at a concentration of 0.8% reduced the MSU-increased expression of phosphorylated NF-κB in the nuclear and cytosolic fractions by 1.25- and 1.27-fold, respectively, while it also reduced the MSU-decreased expression of IκBα in the cytosolic fraction by 1.12-fold. In vivo , MSU crystals increased the number of leukocytes, as well as the concentrations of KC, MIP1α, and IL-6 in pouch fluids, while ethanol (5 g/kg body weight) considerably inhibited the MSU crystal-induced inflammation. These results strongly suggest that ethanol suppresses the secretion of inflammatory cytokines induced by MSU crystals via a pathway including MAPK (p38, JNK, and ERK1/2, especially p38) and NF-κB.
- Published
- 2018
23. 痛風患者におけるABCG2遺伝子多型とメタボリックシンドローム
- Author
-
Zenta Tsutsumi, Takuhito Shoji, Hidenori Koyama, Yuji Moriwaki, and Tetsuya Yamamoto
- Published
- 2018
24. [Untitled]
- Author
-
Tomoya Hamaguchi and Yuji Moriwaki
- Published
- 2010
25. Close relationship between serum concentrations of 1,5-anhydroglucitol and uric acid in non-diabetic male subjects implies common renal transport system
- Author
-
Yuji Moriwaki, Jun Murai, Tetsuya Yamamoto, Masafumi Koga, Soji Kasayama, Mikio Mukai, and Hiroshi Saito
- Subjects
Adult ,Blood Glucose ,Male ,medicine.medical_specialty ,Clinical Biochemistry ,Deoxyglucose ,Biochemistry ,Excretion ,chemistry.chemical_compound ,Renal transport ,Internal medicine ,medicine ,Humans ,Hyperuricemia ,Glucose tolerance test ,medicine.diagnostic_test ,Biochemistry (medical) ,Biological Transport ,General Medicine ,Metabolism ,Glucose Tolerance Test ,Middle Aged ,medicine.disease ,Uric Acid ,Kidney Tubules ,Endocrinology ,chemistry ,1,5-Anhydroglucitol ,Uric acid ,Non diabetic - Abstract
Background 1,5-Anhydroglucitol is found in food. We determined factors other than glucosuria that affect serum 1,5-anhydroglucitol (1,5-AG) concentration. Methods The relationships between serum 1,5-AG concentration and metabolic parameters were investigated in 158 males with normal glucose tolerance verified by an oral glucose tolerance test. Results Serum uric acid was positively correlated to 2-h plasma glucose and serum 1,5-AG concentrations. Serum 1,5-AG levels were not different between hyperuricemic and normouricemic subjects, though those with normouricemia had lower 2-h plasma glucose concentrations than subjects with hyperuricemia. The association between 1,5-AG and uric acid in serum was still evident after adjustment with 2-h plasma glucose concentration. Multivariate regression analyses demonstrated that serum uric acid was an independent variable related to serum 1,5-AG and vice versa. Conclusions 1,5-AG and uric acid may share in part a common renal tubular transport system, independent of glucose excretion.
- Published
- 2009
26. Gene counseling for a pregnant woman with partial deficiency of Hypoxanthine-guanine phosphoribosyltransferase (HPRT)
- Author
-
Sumio Takahashi, Tomoko Tamaoki-Hashimoto, Zenta Tsutsumi, Taku Inokuchi, Yuji Moriwaki, Tsuneyoshi Ka, and Tetsuya Yamamoto
- Subjects
Genetics ,Hypoxanthine-guanine phosphoribosyltransferase ,Biology ,Gene - Published
- 2009
27. 21-Hydroxylase Deficiency Presenting as an Adrenal Incidentaloma
- Author
-
Taku Inokuchi, Asako Yamamoto, Sumio Takahashi, Seiichi Hirota, Yuji Moriwaki, Mayumi Shincho, Zenta Tsutsumi, Hiroki Shima, Takashi Yamamoto, Tsuneyoshi Ka, and Shingo Yamamoto
- Subjects
Mutational analysis ,medicine.medical_specialty ,Endocrinology ,biology ,business.industry ,Endocrinology, Diabetes and Metabolism ,Internal medicine ,21-Hydroxylase ,biology.protein ,Medicine ,Adrenal incidentaloma ,business - Published
- 2008
28. Sporadic Pseudohypoparathyroidism Type Ib With TSH Resistance
- Author
-
Taku Inokuchi, Yuji Moriwaki, Sumio Takahashi, Tsuneyoshi Ka, Asako Yamamoto, Takashi Yamamoto, and Zenta Tsutsumi
- Subjects
Genetics ,medicine.medical_specialty ,biology ,business.industry ,Endocrinology, Diabetes and Metabolism ,TSH RESISTANCE ,Methylation ,medicine.disease ,Endocrinology ,Internal medicine ,medicine ,GNAS complex locus ,biology.protein ,Identification (biology) ,business ,Pseudohypoparathyroidism - Published
- 2007
29. Effects of sucrose on plasma concentrations and urinary excretion of purine bases
- Author
-
Tuneyoshi Ka, Sumio Takahashi, Hiroki Saito, Taku Inokuchi, Asako Yamamoto, Terumi Kobayashi, Yuji Moriwaki, Tetsuya Yamamoto, and Zenta Tsutsumi
- Subjects
Adult ,Male ,Purine ,Sucrose ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Sodium ,Allopurinol ,Xanthine ,Uridine ,Excretion ,chemistry.chemical_compound ,Endocrinology ,chemistry ,Purines ,Internal medicine ,Blood plasma ,medicine ,Humans ,Uric acid ,Hypoxanthine ,medicine.drug - Abstract
To determine whether an increase in the plasma concentration of uric acid by sucrose intake is ascribable to enhanced purine degradation and/or decreased urinary excretion of uric acid, we measured the plasma concentrations of purine bases (uric acid, hypoxanthine, and xanthine) and uridine, as well as the urinary excretion of purine bases in 7 healthy subjects before and after administering sucrose at 1.5 g/kg of body weight in 2 related experiments, with and without an administration of 300 mg of allopurinol. In addition, in the control experiment without an administration of sugar and with an administration of 300 mg of allopurinol, we measured the same parameters in those 7 subjects. Without added allopurinol, sucrose increased the plasma concentration of uric acid by 11% (P
- Published
- 2007
30. Partial HPRT Deficiency with a Novel Mutation of the HPRT Gene in Combination with Four Previously Reported Variants Associated with Hyperuricemia
- Author
-
Hidenori Koyama, Miki Hatayama, Tetsuya Yamamoto, Mitsuyoshi Namba, Takuhito Shoji, Hirokazu Okazaki, Tomitaka Nakayama, Masafumi Kurajoh, and Yuji Moriwaki
- Subjects
musculoskeletal diseases ,Male ,Hypoxanthine Phosphoribosyltransferase ,Adolescent ,Gout ,cells ,genetic processes ,Mutation, Missense ,Hyperuricemia ,medicine.disease_cause ,chemistry.chemical_compound ,Benzbromarone ,Internal Medicine ,medicine ,Humans ,Point Mutation ,Hypoxanthine ,Genetics ,Mutation ,business.industry ,nutritional and metabolic diseases ,General Medicine ,Sequence Analysis, DNA ,medicine.disease ,enzymes and coenzymes (carbohydrates) ,genomic DNA ,chemistry ,Hypoxanthine-guanine phosphoribosyltransferase ,Febuxostat ,business ,medicine.drug - Abstract
A 15-year-old boy was referred to our department due to gout. The laboratory findings showed hyperuricemia with a decreased erythrocyte hypoxanthine phosphoribosyl transferase (HPRT) activity. The HPRT cDNA sequence was revealed to be 206A>T, which has not been previously reported. In addition, direct sequencing of genomic DNA showed the patient to possess four variants reported to be associated with hyperuricemia. This is the first case report of partial HPRT deficiency due to a novel HPRT mutation accompanied by variants associated with hyperuricemia. Combination treatment consisting of benzbromarone and febuxostat had a significant effect in reducing the urate level in our patient.
- Published
- 2015
31. Effects of febuxostat on serum urate level in Japanese hyperuricemia patients
- Author
-
Masaaki Inaba, Yuji Moriwaki, Ikuo Mineo, Yuji Hidaka, Kenshi Higami, Takanori Ueda, Hisashi Yamanaka, Tatsuo Hosoya, Akira Ohtawara, Tetsuya Yamamoto, Atsuo Taniguchi, Hazime Nishikawa, Hirokazu Kakuta, Hiroshi Ooyama, Takahiro Yamauchi, Eiji Ishimura, and Shin Fujimori
- Subjects
Adult ,Male ,medicine.medical_specialty ,Serum urate level ,Urology ,Hyperuricemia ,Pharmacology ,Gout Suppressants ,chemistry.chemical_compound ,Febuxostat ,Rheumatology ,Japan ,Prevalence ,Medicine ,Humans ,Adverse effect ,business.industry ,Middle Aged ,medicine.disease ,Gout ,Uric Acid ,Serum urate ,Treatment Outcome ,chemistry ,Male patient ,Uric acid ,Female ,business ,medicine.drug - Abstract
We assessed the efficacy and adverse effects of febuxostat in male hyperuricemia patients.This was a 12-week, multicenter, open-label, uncontrolled study. The enrolled subjects were 89 hyperuricemic male patients (12 overexcretors, 56 normal excretors, and 21 underexcretors). The endpoint was percent change in serum urate level.The concentration of urate in serum before and 12 weeks after beginning administration of febuxostat in the overexcretors was 9.34 ± 1.48 and 5.59 ± 1.17 mg/dl, respectively, while those were 8.59 ± 1.24 and 5.41 ± 1.35 mg/dl, respectively, in the normal excretors, and 8.29 ± 1.01and 5.11 ± 1.71 mg/dl, respectively, in the underexcretors. After 12 weeks, the rate of change in serum urate after beginning administration of febuxostat was - 0.384 ± 0.186 in the overexcretors, - 0.368 ± 0.128 in the normal excretors, and - 0.365 ± 0.217 in the underexcretors, with no significant differences among them. A common adverse event related to febuxostat was gout flare.Febuxostat effectively reduced the concentration of urate in serum in hyperuricemic patients regardless of the level of uric acid excreted in urine without severe adverse effects.
- Published
- 2015
32. Plasma concentrations and urinary excretion of purine bases (uric acid, hypoxanthine, and xanthine) and oxypurinol after rigorous exercise
- Author
-
Mitsuharu Kaya, Sumio Takahashi, Tuneyoshi Ka, Tetsuya Yamamoto, Yoshitaka Oku, Yuji Moriwaki, Junzou Tsuzita, Zenta Tsutsumi, Asako Yamamoto, and Taku Inokuchi
- Subjects
Adult ,Male ,Purine ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Oxypurinol ,Allopurinol ,Excretion ,Norepinephrine ,chemistry.chemical_compound ,Endocrinology ,Adenine nucleotide ,Internal medicine ,Blood plasma ,medicine ,Humans ,Lactic Acid ,Exercise ,Hypoxanthine ,Xanthine ,Uric Acid ,chemistry ,Purines ,Creatinine ,Hypoxanthines ,Xanthines ,Uric acid ,medicine.drug - Abstract
To investigate the effects of exercise on the plasma concentrations and urinary excretion of purine bases and oxypurinol, we performed 3 experiments with 6 healthy male subjects. The first was a combination of allopurinol intake (300 mg) and exercise (VO2max, 70%) (combination experiment), the second was exercise alone (exercise-alone experiment), and the third was allopurinol intake alone (allopurinol-alone experiment). In the combination experiment, exercise increased the concentrations of purine bases and noradrenaline in plasma, as well as lactic acid in blood and the urinary excretion of oxypurines, whereas it decreased the urinary excretion of uric acid and oxypurinol as well as the fractional excretion of hypoxanthine, xanthine, uric acid, and oxypurinol. In the exercise-alone experiment, exercise increased the concentrations of purine bases and noradrenaline in plasma, lactic acid in blood, and the urinary excretion of oxypurines, whereas it decreased the urinary excretion of uric acid and fractional excretion of purine bases. In contrast, in the allopurinol-alone experiment, the plasma concentration, urinary excretion, and fractional excretion of purine bases and oxypurinol remained unchanged. These results suggest that increases in adenine nucleotide degradation and lactic acid production, as well as a release of noradrenaline caused by exercise, contribute to increases in plasma concentration and urinary excretion of oxypurines and plasma concentration of urate, as well as decreases in urinary excretion of uric acid and oxypurinol, along with fractional excretion of uric acid, oxypurinol, and xanthine. In addition, they suggest that oxypurinol does not significantly inhibit the exercise-induced increase in plasma concentration of urate.
- Published
- 2006
33. Relationship between acidic urine and insulin resistance in gout patients
- Author
-
Sumio Takahashi, Tetsuya Yamamoto, Yuji Moriwaki, Tsuneyoshi Ka, Taku Inokuchi, and Zenta Tsutsumi
- Subjects
medicine.medical_specialty ,Endocrinology ,Insulin resistance ,business.industry ,Internal medicine ,Medicine ,Urine ,business ,medicine.disease ,Gout - Published
- 2006
34. Multicentric Castleman disease mimicking IgG4-related disease: A case report
- Author
-
Yasumori Izumi, Daisuke Niino, Chieko Kawahara, Yuji Moriwaki, Hirokazu Kurohama, Keiko Hisatomi, Hayato Takeshita, Masakazu Matsuda, Yoshika Shigemitsu, Natsuki Yamashita, Masahiro Ito, Nozomi Iwanaga, Atsushi Kawakami, and Kiyoshi Migita
- Subjects
Pathology ,medicine.medical_specialty ,Biopsy ,Plasma Cells ,Plasma cell ,Autoimmune Diseases ,Diagnosis, Differential ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Rheumatology ,Fluorodeoxyglucose F18 ,Hypergammaglobulinemia ,medicine ,Rheumatoid factor ,Humans ,Glucocorticoids ,030203 arthritis & rheumatology ,medicine.diagnostic_test ,biology ,business.industry ,Interleukin-6 ,Castleman Disease ,Middle Aged ,medicine.disease ,Vascular endothelial growth factor ,medicine.anatomical_structure ,C-Reactive Protein ,chemistry ,030220 oncology & carcinogenesis ,Immunoglobulin G ,Positron-Emission Tomography ,biology.protein ,IgG4-related disease ,Female ,Lymph ,Lymph Nodes ,Antibody ,business - Abstract
A 50-year-old woman was referred to our hospital for shoulder joint stiffness. She had a history of polyclonal hypergammaglobulinemia and an elevated C-reactive protein level. Her laboratory data revealed an elevated serum immunoglobulin G4 (IgG4) level, hypergammaglobulinemia, and rheumatoid factor positivity in the absence of anticyclic citrullinated peptide antibody. [18F]-Fluorodeoxyglucose positron emission tomography showed significant [18F]-fluorodeoxyglucose uptake in multiple lymph nodes (axillary, hilar, para-aortic, and inguinal). Biopsy of the inguinal lymph node showed expansion of the interfollicular areas by heavily infiltrating plasma cells, consistent with multicentric Castleman disease (MCD). Immunohistochemical analysis revealed a 37.3% IgG4-positive:IgG-positive plasma cell ratio, indicating overlapping IgG4-related disease. However, serological cytokine analysis revealed elevated levels of interleukin-6 (9.3 pg/ml) and vascular endothelial growth factor (VEGF) (1210 pg/ml), which are compatible with MCD. Corticosteroid treatment resolved the serological and imaging abnormalities. IgG4-related disease can mimic MCD, and it is crucial to distinguish between these two diseases. Serum interleukin-6 and VEGF levels may help to discriminate MCD from IgG4-related disease.
- Published
- 2014
35. Effect of ethanol on metabolism of purine bases (hypoxanthine, xanthine, and uric acid)
- Author
-
Tetsuya Yamamoto, Yuji Moriwaki, and Sumio Takahashi
- Subjects
Purine ,medicine.medical_specialty ,Xanthine Dehydrogenase ,Clinical Biochemistry ,Alcohol ,Hyperuricemia ,Xanthine ,Biochemistry ,chemistry.chemical_compound ,Acetyl Coenzyme A ,Adenine nucleotide ,Internal medicine ,medicine ,Humans ,Lactic Acid ,Hypoxanthine ,Ethanol ,Chemistry ,Aldehyde Dehydrogenase, Mitochondrial ,Biochemistry (medical) ,Alcohol Dehydrogenase ,General Medicine ,Xanthine dehydrogenase activity ,Aldehyde Dehydrogenase ,NAD ,medicine.disease ,Uric Acid ,Endocrinology ,Uric acid ,Oxidation-Reduction - Abstract
There are many factors that contribute to hyperuricemia, including obesity, insulin resistance, alcohol consumption, diuretic use, hypertension, renal insufficiency, genetic makeup, etc. Of these, alcohol (ethanol) is the most important. Ethanol enhances adenine nucleotide degradation and increases lactic acid level in blood, leading to hyperuricemia. In beer, purines also contribute to an increase in plasma uric acid. Although rare, dehydration and ketoacidosis (due to ethanol ingestion) are associated with the ethanol-induced increase in serum uric acid levels. Ethanol also increases the plasma concentrations and urinary excretion of hypoxanthine and xanthine via the acceleration of adenine nucleotide degradation and a possible weak inhibition of xanthine dehydrogenase activity. Since many factors such as the ALDH2*1 gene and ADH2*2 gene, daily drinking habits, exercise, and dehydration enhance the increase in plasma concentration of uric acid induced by ethanol, it is important to pay attention to these factors, as well as ingested ethanol volume, type of alcoholic beverage, and the administration of anti-hyperuricemic agents, to prevent and treat ethanol-induced hyperuricemia.
- Published
- 2005
36. Oxidized low-density lipoprotein autoantibodies in patients with primary gout: effect of urate-lowering therapy
- Author
-
Zenta Tsutsumi, Sumio Takahashi, Yuji Moriwaki, Tetsuya Yamamoto, and Tsuneyoshi Ka
- Subjects
Male ,musculoskeletal diseases ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Antioxidant ,Gout ,Allopurinol ,medicine.medical_treatment ,Clinical Biochemistry ,Biochemistry ,Antioxidants ,Benzbromarone ,chemistry.chemical_compound ,Internal medicine ,medicine ,Humans ,Hyperuricemia ,Triglycerides ,Autoantibodies ,Cholesterol ,Body Weight ,Cholesterol, HDL ,Smoking ,Biochemistry (medical) ,Autoantibody ,nutritional and metabolic diseases ,Cholesterol, LDL ,General Medicine ,Middle Aged ,medicine.disease ,Uric Acid ,Lipoproteins, LDL ,Endocrinology ,chemistry ,Case-Control Studies ,Uric acid ,medicine.drug - Abstract
Background: Uric acid is a strong scavenger of reactive oxygen species, which are known to contribute to the development of atherosclerosis, while the incidence of atherosclerotic diseases is rather high in patients with gout. Among the established risk factors for atherosclerosis, oxidized LDL is believed to play a major role in its development and progression. Allopurinol and its active metabolite, oxypurinol, have been suggested to possess an antioxidant ability to scavenge the hydroxyl radical. Therefore, allopurinol may be beneficial in the prevention of LDL oxidation, as well as in the treatment of hyperuricemia. The objective of this work was to determine the degree of LDL oxidation in gout and the effect of allopurinol on LDL oxidation. Methods: Age-matched male patients with primary intercritical gout and healthy male adults were included in the study. The serum concentrations of oxidized LDL autoantibodies and total antioxidant status were measured using an enzyme immunoassay. Results: Serum concentrations of oxidized LDL autoantibodies were significantly higher in patients with gout than the control subjects (p
- Published
- 2004
37. Immunohistochemical Demonstration of Adenosine Deaminase (ADA1) in Human Tissues
- Author
-
Sumio Takahashi, Toshikazu Hada, Zenta Tsutsumi, Tetsuya Yamamoto, Yuji Moriwaki, and Tsuneyoshi Ka
- Subjects
Pathology ,medicine.medical_specialty ,Histology ,biology ,Physiology ,Cell Biology ,Biochemistry ,Adenosine ,Small intestine ,Pathology and Forensic Medicine ,Adenosine deaminase ,medicine.anatomical_structure ,Polyclonal antibodies ,Parenchyma ,biology.protein ,medicine ,Immunohistochemistry ,Nucleoside ,Keyhole limpet hemocyanin ,medicine.drug - Abstract
The localization of adenosine deaminase (ADA 1) in human tissues was investigated by an immunohistochemical method. Tissues were taken from cadavers, fixed with 4% paraformaldehyde-PBS, and embedded in paraffin, and then examined following immunoperoxidase staining using a rabbit polyclonal antibody against keyhole limpet hemocyanin (KLH)-peptide conjugate (Ser-Phe-Leu-Pro-Glu-Asp-Glu-Lys-Arg-Glu-Leu-Leu) constructed from a human adenosine deaminase cDNA sequence. Immunohistochemical analysis demonstrated that ADA 1 was distributed in various human tissues, with intense reactivity observed in surface epithelia of the esophagus, stomach, small intestine, renal tubules, glandular cells of the small intestine, endothelial lining cells of the liver, and alveoli of the lung. Moderate reactivity was observed in the glomerulus cells of the kidney, epithelia and glandular cells of the large intestine, and hepatic parenchymal cells. This ubiquitous but cell-specific localization suggests that ADA 1 plays an important role in selected cells through the degradation of adenosine, a pharmacological active nucleoside.
- Published
- 2004
38. Identification of a new point mutation in the human molybdenum cofactor sulferase gene that is responsible for xanthinuria type II
- Author
-
Toshikazu Hada, Zenta Tsutsumi, Ka Tuneyoshi, Tetsuya Yamamoto, Kiyoshi Matsui, Yuji Moriwaki, Jidong Cheng, and Sumio Takahashi
- Subjects
Adult ,Purine-Pyrimidine Metabolism, Inborn Errors ,Xanthine Oxidase ,medicine.medical_specialty ,DNA, Complementary ,Antimetabolites ,Duodenum ,Xanthine Dehydrogenase ,Allopurinol ,Endocrinology, Diabetes and Metabolism ,Immunoblotting ,Biology ,chemistry.chemical_compound ,Endocrinology ,Internal medicine ,medicine ,Humans ,Point Mutation ,Xanthinuria ,Intestinal Mucosa ,Hypouricemia ,Xanthine oxidase ,Aldehyde oxidase ,DNA Primers ,Hypoxanthine ,Xanthine dehydrogenase activity ,medicine.disease ,Uric Acid ,Aldehyde Oxidase ,chemistry ,Xanthine dehydrogenase ,Biochemistry ,Sulfurtransferases ,Xanthines ,Female ,Molybdenum cofactor ,medicine.drug - Abstract
A 43-year-old xanthinuric female was referred to our department because of hypouricemia. Routine laboratory data showed hypouricemia, a high level of plasma oxypurines, decreased urinary uric acid excretion, and increased urinary oxypurine excretion, with xanthine dehydrogenase activity in the duodenal mucosa below the limits of detection. In addition, allopurinol was not metabolized. From these findings, the patient was diagnosed with xanthinuria type II. To investigate the properties of xanthine dehydrogenase/xanthine oxidase (XDH/XO) deficiency, a cDNA sequence encoding XDH/XO, aldehyde oxidase (AO), and molybdenum cofactor sulferase (MCS), as well as immunoblotting analysis for XDH/XO protein, obtained from duodenal mucosa samples were performed. The XDH/XO cDNA and AO cDNA sequences of the xanthinuric patient were consistent with previously reported ones, whereas the MCS cDNA sequence revealed a point mutation of G to C in nucleotide 466, which changed codon 156 from GCC (Ala) to CCC (Pro). In addition, the MCS genomic DNA sequence including the site of the mutation revealed the same, suggesting that the xanthinuric patient was homozygous for this mutation. Such findings have not been previously reported for patients with xanthinuria type II.
- Published
- 2003
39. Elevated levels of interleukin-18 and tumor necrosis factor-α in serum of patients with type 2 diabetes mellitus: Relationship with diabetic nephropathy
- Author
-
Toshikazu Hada, Yuhei Shibutani, Eiji Aoki, Takashi Yamamoto, Masafumi Koga, Minoru Fukuchi, Sumio Takahashi, Zenta Tsutsumi, Haruki Okamura, and Yuji Moriwaki
- Subjects
Adult ,Male ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Enzyme-Linked Immunosorbent Assay ,Nephropathy ,Diabetic nephropathy ,chemistry.chemical_compound ,Endocrinology ,Internal medicine ,Diabetes mellitus ,medicine ,Albuminuria ,Humans ,Diabetic Nephropathies ,Creatinine ,Interleukin-6 ,Tumor Necrosis Factor-alpha ,business.industry ,Interleukin-18 ,Albumin ,Interleukin ,Middle Aged ,medicine.disease ,Lipids ,Diabetes Mellitus, Type 2 ,chemistry ,Female ,Microalbuminuria ,medicine.symptom ,business - Abstract
To compare levels of interleukin (IL)-18, tumor necrosis factor-alpha (TNF-alpha), and IL-6 in serum, we studied 151 type 2 diabetes mellitus patients with various degrees of nephropathy, as well as 80 healthy volunteers. IL-18, TNF-alpha, and IL-6 in serum were measured using an enzyme-linked immunosorbent assay (ELISA) with the respective mouse monoclonal antibodies. Significant differences in serum levels of IL-18 and TNF-alpha were observed between the patients and control subjects (IL-18, 278.0 +/- 11.9 pg/mL v 172.8 +/- 7.7 pg/mL, P.0001; TNF-alpha, 2.41 +/- 0.18 pg/mL v 0.46 +/- 0.18 pg/mL, P.0001), whereas that of IL-6 was not different between the two groups (0.73 +/- 0.10 pg/mL v 0.65 +/- 0.08 pg/mL, difference not significant [NS]), although patients with nephropathy showed higher levels. In addition, IL-18 levels were increased in diabetic patients with the development of urinary albumin excretion, with the highest found in those with microalbuminuria (30 micro g/mg creatinine, 252.7 +/- 16.4 pg/mL; 30 to300 micro g/mg creatinine, 352.7 +/- 35.2 pg/mL;300 micro g/mg creatinine, 350.0 +/- 16.0 pg/mL). Similarly, TNF-alpha and IL-6 in diabetic patients with microalbuminuria or clinical albuminuria were significantly increased as compared with those without albuminuria (TNF-alpha, 3.20 +/- 0.41 pg/mL v 1.94 +/- 0.18 pg/mL; IL-6, 1.64 +/- 1.11 pg/mL v 0.51 +/- 0.05 pg/mL, P.05, respectively). These results suggest that serum levels of IL-18, TNF-alpha, and IL-6 may have some etiopathogenic roles in diabetic nephropathy.
- Published
- 2003
40. Effect of Octreotide Acetate on the Plasma Concentration and Urinary Excretion of Uridine and Purine Bases
- Author
-
Zenta Tsutsumi, Yuji Moriwaki, Toshikazu Hada, Tsuneyoshi Ka, Sumio Takahashi, and Tetsuya Yamamoto
- Subjects
Adult ,Blood Glucose ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Octreotide acetate ,Octreotide ,Glucagon ,chemistry.chemical_compound ,Endocrinology ,Chlorides ,Internal medicine ,Pyruvic Acid ,Cyclic AMP ,medicine ,Humans ,Insulin ,Lactic Acid ,Uridine ,Hypoxanthine ,Sodium ,Middle Aged ,Xanthine ,Hormones ,chemistry ,Purines ,Creatinine ,Uric acid ,Pyruvic acid ,medicine.drug - Abstract
To determine the effect of octreotide acetate on urinary excretion of uric acid and plasma concentration of uridine, we subcutaneously administered octreotide acetate (1 microg/kg of body weight) to 5 healthy subjects. Ninety minutes after administration, octreotide acetate increased the plasma concentration of uridine by 15% and decreased the plasma concentration of glucagon by 24% and that of insulin to below the detection limits. In addition, octreotide acetate decreased the urinary excretion of uric acid, sodium, and chloride by 60%, 40%, and 38%, respectively, at 1 hour after administration. However, octreotide acetate did not affect the concentrations of hypoxanthine, xanthine, uric acid, cyclic AMP in plasma, lactic acid and pyruvic acid in blood, urinary excretion of hypoxanthine and xanthine, or creatinine clearance. From these results, we speculated that octreotide acetate decreases the urinary excretion of uric acid by decreasing the concentration of glucagon and/or urinary excretion of sodium, and increases the plasma concentration of uridine via decreased concentrations of glucagon and insulin.
- Published
- 2002
41. Japanese Society of Hematology
- Author
-
Junya Makiyama, Yoshitaka Imaizumi, Hideki Tsushima, Jun Taguchi, Yasushi Sawayama, Daisuke Imanishi, Tomoko Hata, Yasushi Miyazaki, Yuji Moriwaki, Hiroaki Taniguchi, and Kunihiro Tsukasaki
- Subjects
Male ,medicine.medical_specialty ,Vincristine ,medicine.medical_treatment ,Ranimustine ,Maintenance Chemotherapy ,chemistry.chemical_compound ,Prednisone ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Chemotherapy ,Humans ,Leukemia-Lymphoma, Adult T-Cell ,Cyclophosphamide ,Aged ,Neoplasm Staging ,Retrospective Studies ,Aged, 80 and over ,business.industry ,Age Factors ,Induction chemotherapy ,Hematology ,Induction Chemotherapy ,Middle Aged ,Carboplatin ,Surgery ,Elderly patients ,Regimen ,Treatment Outcome ,chemistry ,Doxorubicin ,Adult T cell leukemia-lymphoma (ATL) ,Disease Progression ,Vindesine ,Female ,business ,medicine.drug - Abstract
VCAP (vincristine, cyclophosphamide, doxorubicin, and prednisone)-AMP (doxorubicin, ranimustine, and prednisone)-VECP (vindesine, etoposide, carboplatin, and prednisone) is a standard regimen for aggressive adult T cell leukemia-lymphoma (ATL). However, the efficacy of this regimen has not been fully elucidated for patients aged 70 years or older. Here, we retrospectively analyzed elderly patients with aggressive ATL at Nagasaki University Hospital between 1994 and 2010 to assess treatment outcomes. Of 148 evaluable patients, 54 were aged 70 years or older at diagnosis. The median survival time (MST) and overall survival (OS) at 2 years in elderly patients were 10.6 months and 22.1 %, respectively. Thirty-four patients received VCAP-AMP-VECP as the initial treatment, although the doses were reduced for most patients. In these patients, MST and OS at 2 years were 13.4 months and 26.6 %, respectively. Eleven of 34 patients (32 %) received maintenance oral chemotherapy after two or three cycles of VCAP-AMP-VECP, and MST and OS at 2 years were 16.7 months and 32.7 %, respectively. Our results suggest that the VCAP-AMP-VECP regimen may be effective and that maintenance oral chemotherapy may be considered as a therapeutic option for elderly patients with aggressive ATL., International Journal of Hematology, 100(5), pp.464-472; 2014
- Published
- 2014
42. Plasma brain-derived neurotrophic factor and reverse dipping pattern of nocturnal blood pressure in patients with cardiovascular risk factors
- Author
-
Takuhito Shoji, Jun Shiraishi, Mitsuyoshi Namba, Akinori Kanzaki, Miki Hatayama, Tetsuya Yamamoto, Hirokazu Okazaki, Masaaki Inaba, Hidenori Koyama, Masafumi Kurajoh, Yuji Moriwaki, and Manabu Kadoya
- Subjects
Male ,medicine.medical_specialty ,Peptide Hormones ,lcsh:Medicine ,Blood Pressure ,Autonomic Nervous System ,Nervous System ,Biochemistry ,Vascular Medicine ,Heart Rate ,Risk Factors ,Diabetes mellitus ,Internal medicine ,Blood plasma ,Heart rate ,medicine ,Medicine and Health Sciences ,Humans ,Risk factor ,lcsh:Science ,Brain-derived neurotrophic factor ,Multidisciplinary ,business.industry ,Brain-Derived Neurotrophic Factor ,Neuropeptides ,lcsh:R ,Biology and Life Sciences ,Neurochemistry ,Blood Pressure Determination ,Blood Pressure Monitoring, Ambulatory ,Middle Aged ,medicine.disease ,Hormones ,Autonomic nervous system ,Blood pressure ,Endocrinology ,Cross-Sectional Studies ,Cardiovascular Diseases ,Hypertension ,Female ,lcsh:Q ,Anatomy ,Neurochemicals ,business ,Dyslipidemia ,Research Article - Abstract
Context Basic studies have shown that brain-derived neurotrophic factor (BDNF) has critical roles in the survival, growth, maintenance, and death of central and peripheral neurons, while it is also involved in regulation of the autonomic nervous system. Furthermore, recent clinical studies have suggested potential role of plasma BDNF in the circulatory system. Objective We investigated the mutual relationships among plasma BDNF, patterns of nocturnal blood pressure changes (dippers, non-dippers, extra-dippers, and reverse-dippers), and cardiac autonomic function as determined by heart rate variability (HRV). Design This was a cross-sectional study of patients registered in the Hyogo Sleep Cardio-Autonomic Atherosclerosis (HSCAA) Study from October 2010 to November 2012. Patients Two-hundred fifty patients with 1 or more cardiovascular risk factor(s) (obesity, smoking, presence of cardiovascular event history, hypertension, dyslipidemia, diabetes mellitus, chronic kidney disease) were enrolled. Results Plasma BDNF levels (natural logarithm transformed) were significantly (p = 0.001) lower in reverse-dipper patients (7.18±0.69 pg/ml, mean ± SD, n = 36) as compared to dippers (7.86±0.86 pg/ml, n = 100). Multiple logistic regression analysis showed that BDNF (odds ratios: 0.417, 95% confidence interval: 0.228–0.762, P = 0.004) was the sole factor significantly and independently associated with the reverse-dippers as compared with dippers. Furthermore, plasma BDNF level was significantly and positively correlated with the time-domain (SDNN, SDANN5, CVRR) and frequency-domain (LF) of HRV parameters. Finally, multiple logistic regression analyses showed that the relationship between plasma BDNF and the reverse-dippers was weakened, yet remained significant or borderline significant even after adjusting for HRV parameters. Conclusions Low plasma BDNF was independently associated with patients showing a reverse-dipper pattern of nocturnal blood pressure, in which an imbalance of cardiac autonomic function may be partly involved.
- Published
- 2014
43. Effects on Uric Acid Metabolism of the Drugs except the Antihyperuricemics
- Author
-
Yuji Moriwaki
- Subjects
Side effect ,nutritional and metabolic diseases ,Pharmaceutical Science ,Metabolism ,Absorption (skin) ,Pharmacology ,Biology ,urologic and male genital diseases ,medicine.disease ,Gout ,chemistry.chemical_compound ,chemistry ,medicine ,Uric acid ,Hyperuricemia ,Hypouricemia ,Uric acid excretion - Abstract
A number of drugs commonly used in clinical practice can affect the serum concentration of uric acid. Some raise serum uric acid level by an increase in uric acid production or a decrease in uric acid excretion, while others lower serum uric acid level by an increase in uric acid excretion or decrease in uric acid absorption from intestine. In addition, salicylate shows so-called “biphasic effect”. At small doses it raises serum uric acid level, while at higher doses it lowers serum uric acid concentration. To understand the effects of those pharmacological agents on uric acid metabolism will help to avoid unexpected side effect of hyperuricemia and gout flare. In addition, hypouricemic property of some drugs may obviate the need for polypharmacy and improve the medication compliance.
- Published
- 2014
44. Human xanthine dehydrogenase cDNA sequence and protein in an atypical case of type I xanthinuria in comparison with normal subjects
- Author
-
Zenta Tsutsumi, Tetsuya Yamamoto, Kiyoshi Matsui, Taro Ueo, Yuichi Shibutani, Sumio Takahashi, Toshikazu Hada, and Yuji Moriwaki
- Subjects
Purine ,DNA, Complementary ,Xanthine Dehydrogenase ,Clinical Biochemistry ,Biology ,Polymerase Chain Reaction ,Biochemistry ,chemistry.chemical_compound ,Reference Values ,Complementary DNA ,Gene expression ,medicine ,Humans ,RNA, Messenger ,Xanthinuria ,Hypouricemia ,Xanthine oxidase ,Hypoxanthine ,DNA Primers ,Base Sequence ,Biochemistry (medical) ,General Medicine ,medicine.disease ,Molecular biology ,chemistry ,Xanthine dehydrogenase ,Xanthines - Abstract
To investigate the properties of xanthine dehydrogenase/xanthine oxidase (XDH/XO) deficiency in a patient with atypical type I xanthinuria, as indicated by oxypurine data, a cDNA sequence encoding XDH, XDH/XO immunoblot analysis and a competitive PCR assay were performed, and the results were compared with those of normal subjects. The xanthine dehydrogenase cDNA sequence of the patient was consistent with the controls, while immunologically reactive 150 kD XDH/XO protein was not present in the xanthinuric duodenal mucosa, unlike the control duodenal mucosa. In addition, a decrease in XDH/XO messenger RNA was found by competitive PCR. These results suggest that atypical type I xanthinuria is due to a decrease in messenger RNA of XDH/XO. Furthermore, it was considered that this decrease could explain the normal plasma level and near normal urinary excretion of hypoxanthine seen in this case of xanthinuria, though XDH/XO activity and protein were not detected spectrophotometrically and immunologically, respectively.
- Published
- 2001
45. Effect of furosemide on renal excretion of oxypurinol and purine bases
- Author
-
Sumio Takahashi, Tetsuya Yamamoto, Zenta Tsutsumi, Yuji Moriwaki, and Toshikazu Hada
- Subjects
Adult ,Male ,Xanthine Oxidase ,medicine.medical_specialty ,Metabolic Clearance Rate ,Allopurinol ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Administration, Oral ,Oxypurinol ,Kidney ,Excretion ,chemistry.chemical_compound ,Endocrinology ,Chlorides ,Furosemide ,Internal medicine ,medicine ,Humans ,Hyperuricemia ,Diuretics ,Aldosterone ,Chemistry ,Angiotensin II ,Sodium ,Kidney metabolism ,Middle Aged ,Xanthine ,medicine.disease ,Uric Acid ,Purines ,Creatinine ,Injections, Intravenous ,Potassium ,Uric acid ,Drug Therapy, Combination ,Diuretic ,medicine.drug - Abstract
To examine whether furosemide affects the plasma concentration and urinary excretion of purine bases and oxypurinol, we administered allopurinol (300 mg) orally to 6 healthy subjects and then administered furosemide (20 mg) intravenously 10 hours later. Furosemide (20 mg) decreased the urinary excretion of uric acid by 40% (P < .01), oxypurinol by 39% (P < .05), and xanthine by 43% (P < .05) and the fractional clearance of uric acid by 45% (P < .01) and oxypurinol by 34% (P < .05) when measured 1 to 2 hours after administration. Moreover, furosemide increased the plasma concentration of uric acid by 6% at 1.5 hours after administration. These results indicate that furosemide may decrease the urinary excretion of uric acid and oxypurinol by acting on their common renal transport pathway(s). In addition, it is suggested that the effect of furosemide on oxypurinol is clinically important, since the hypouricemic effect of allopurinol may become more potent as a result.
- Published
- 2001
46. Erythema multiforme major after treatment with bosutinib: a case report
- Author
-
Shinichiro Yoshida, Yuji Moriwaki, Hideki Kitanosono, Junya Makiyama, and Tetsuo Shukuwa
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Internal medicine ,Medicine ,Hematology ,business ,Bosutinib ,After treatment ,medicine.drug - Published
- 2016
47. Basedow's Disease and Chronic Ulcerative Colitis. A Case Report and Review of the Japanese Literature
- Author
-
Sumio Takahashi, Toshikazu Hada, Hiroko Iijima, Masako Nishimura, Tetsuya Yamamoto, and Yuji Moriwaki
- Subjects
Adult ,Diarrhea ,Male ,endocrine system ,medicine.medical_specialty ,Pathology ,endocrine system diseases ,Prednisolone ,Graves' disease ,Anti-Inflammatory Agents ,Comorbidity ,Thyroid Function Tests ,Hyperthyroidism ,Inflammatory bowel disease ,Gastroenterology ,Thyroid function tests ,Autoimmune Diseases ,Postoperative Complications ,Antithyroid Agents ,Japan ,Internal medicine ,Internal Medicine ,medicine ,Animals ,Humans ,Colitis ,Colectomy ,Methimazole ,medicine.diagnostic_test ,business.industry ,Anti-Inflammatory Agents, Non-Steroidal ,Thyroid ,General Medicine ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Ulcerative colitis ,Graves Disease ,Sulfasalazine ,medicine.anatomical_structure ,Chronic Disease ,Colitis, Ulcerative ,Female ,Thyroid function ,business ,medicine.drug - Abstract
A case of Basedow's disease, that developed after successful treatment of ulcerative colitis with a total colectomy, is presented, along with a review of the Japanese literature on the coexistence of hyperthyroidism and ulcerative colitis. A 26-year-old man was referred to our department, complaining of general fatigue, appetite loss, and palpitation. At age 14, blood was discovered in his stool and a diagnosis of ulcerative colitis was made. Since then, he has been treated with salazosulfapyridine and prednisolone. On examination, mild exophthalmos and thyroid swelling were observed. Both serum free T3 and T4 levels were increased along with a positive TSH receptor antibody, while TSH was decreased. Scintigraphic and ultrasonographic examinations of the thyroid gland showed diffuse enlargement. Treatment with thiamazole relieved the symptoms and normalized the thyroid function. Although a high incidence of autoimmune thyroid diseases in association with ulcerative colitis has been suggested, only 6 cases of hyperthyroidism coexisting with ulcerative colitis have been reported in Japan. A common immunological process has been suggested to be implicated in the pathogenesis of this association, however, the exact mechanism remains unclear.
- Published
- 2001
48. Spontaneous Regression of Hepatic Adenoma in a Patient with Glycogen Storage Disease Type I after Hemodialysis: Ultrasonographic and CT Findings
- Author
-
Takashi Nishigami, Toshikazu Hada, Yuji Moriwaki, Tetsuya Yamamoto, Hiroko Iijima, and Sumio Takahashi
- Subjects
Adult ,medicine.medical_specialty ,Pathology ,Adenoma ,Biopsy ,medicine.medical_treatment ,Glycogen Storage Disease Type I ,Hypoglycemia ,Gastroenterology ,Adenoma, Liver Cell ,Renal Dialysis ,Internal medicine ,Internal Medicine ,medicine ,Humans ,Renal Insufficiency ,Hyperuricemia ,Ultrasonography ,Glycogen storage disease type I ,medicine.diagnostic_test ,business.industry ,Liver Neoplasms ,General Medicine ,medicine.disease ,Liver ,Neoplasm Regression, Spontaneous ,Lactic acidosis ,Liver biopsy ,Female ,Hemodialysis ,Tomography, X-Ray Computed ,business - Abstract
A 23-year-old woman was admitted to our hospital with recurrent gouty arthritis. Laboratory findings showed hypoglycemia, lactic acidosis, hyperlipidemia, and hyperuricemia, with normal values of serum alfa-fetoprotein (AFP) and protein induced by vitamin K absence (PIVKA-II). A diagnosis of glycogen storage disease type I (GSD-type I) was made on the basis of the laboratory data, liver biopsy findings, and partially deficient thrombocyte glucose-6-phosphatase (G-6-Pase) activity. Ultrasonography and computed tomography revealed multiple focal hepatic masses. Biopsied specimens of the lesion demonstrated a hepatic adenoma, which changed in appearance in the relatively short period between echography and computed tomography. This interesting phenomenon may highlight the importance for careful follow-up of hepatic adenomas, because of the potential of rupture, hemorrhage, or malignant transformation. During follow-up, the present patient received hemodialysis due to renal failure, and the adenoma regressed spontaneously after 8 years. Included are diagnostic images, demonstrating the association of hepatic adenoma and GSD-type I.
- Published
- 2001
49. Effect of urine storage on urinary uric acid concentrations
- Author
-
Tetsuya Yamamoto, Jun-ichi Yamakita, Zenta Tsutsumi, Toshikazu Hada, Yuji Moriwaki, and Sumio Takahashi
- Subjects
Male ,Chromatography ,Gout ,Chemistry ,Urinary system ,Clinical Biochemistry ,nutritional and metabolic diseases ,General Medicine ,Metabolism ,Urine ,urologic and male genital diseases ,medicine.disease ,Specimen Handling ,Uric Acid ,Dilution ,Uric acid crystals ,chemistry.chemical_compound ,Biochemistry ,Reference Values ,medicine ,Humans ,Uric acid ,Hyperuricemia - Abstract
Accurate determination of serum and urinary uric acid concentrations is essential for the diagnosis and classification of gout according to uric acid metabolism derangement. Urine and/or serum samples are often kept at either 4°C or 20°C until assayed, when a large number of samples are handled simultaneously. Our preliminary study indicated a significant decrease in urinary uric acid concentration after preservation, regardless of the storage temperature. Uric acid crystals were often observed in these cases which showed a marked decrease in urinary uric acid concentration after storage. In the present study, we sought the factor(s) that might cause this decrease in urinary uric acid concentration, as well as measures to overcome the problem. High urinary uric acid concentration and low pH proved to play major roles in the decrease in urinary uric acid concentration after storage. In contrast, dilution of the urine samples before storage resulted in no significant change in urinary uric acid concentration. Based on these results, we recommend diluting urine before storage for determination of uric acid concentration and avoiding underestimation.
- Published
- 2000
50. Two Cases of Insulinoma Complicated With Adrenal Tumor
- Author
-
Jiro Fujimoto, Sumio Takahashi, Yuji Moriwaki, Nobukazu Kuroda, Taku Inokuchi, Tsuneyoshi Ka, Yasukane Asano, Takashi Yamamoto, and Zenta Tsutsumi
- Subjects
medicine.medical_specialty ,Cushing syndrome ,Nonfunctioning adenoma ,business.industry ,Endocrinology, Diabetes and Metabolism ,Internal medicine ,medicine ,Adrenocorticotropic hormone ,medicine.disease ,business ,Insulinoma ,Gastroenterology - Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.